Literature DB >> 12497546

Infectious pulmonary complications in lung transplant recipients.

Kevin M Chan1, Samuel A Allen.   

Abstract

Pulmonary infections are the most common cause of morbidity in the lung transplant population. Prompt recognition and treatment is necessary to prevent poor outcomes. An understanding of the temporal relationship between immunosuppression and the risk for developing infection can assist the clinician with appropriate treatment. Bacterial pneumonia is common within the first 4 months after transplantation whereas cytomegalovirus (CMV) infection or disease becomes prevalent after the discontinuation of prophylaxis in at-risk patients. Fungal infections, especially aspergillosis, can be fatal if not treated early and the risk for infection is present throughout the transplant period. Community-acquired viral infections present with upper-respiratory symptoms and wheezing that may lead to a chronic decline in lung function. Suspicion of a pulmonary infection in these immunosuppressed individuals should lead to an urgent diagnostic bronchoscopy and empiric antimicrobial therapy. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12497546     DOI: 10.1053/srin.2002.36444

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  7 in total

1.  Machine learning analysis of the relationship between changes in immunological parameters and changes in resistance to Listeria monocytogenes: a new approach for risk assessment and systems immunology.

Authors:  Zhifa Liu; Changhe Yuan; Stephen B Pruett
Journal:  Toxicol Sci       Date:  2012-06-13       Impact factor: 4.849

2.  Antifungal prophylaxis in lung transplant recipients: A systematic review and meta-analysis.

Authors:  Kelly M Pennington; Misbah Baqir; Patricia J Erwin; Raymund R Razonable; Mohammad Hassan Murad; Cassie C Kennedy
Journal:  Transpl Infect Dis       Date:  2020-06-16       Impact factor: 2.228

3.  The Effect of Monthly Anti-CD25+ Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation.

Authors:  D J Ross; J Belperio; C Natori; A Ardehali
Journal:  Int J Organ Transplant Med       Date:  2020

4.  Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis.

Authors:  John P Donnelly; Jayme E Locke; Paul A MacLennan; Gerald McGwin; Roslyn B Mannon; Monika M Safford; John W Baddley; Paul Muntner; Henry E Wang
Journal:  Clin Infect Dis       Date:  2016-05-23       Impact factor: 9.079

5.  Retransplantation Outcomes at a Large Lung Transplantation Program.

Authors:  Dewei Ren; Thomas S Kaleekal; Edward A Graviss; Duc T Nguyen; Neeraj Sinha; Amad Goodarzi; Isioma Agboli; Erik E Suarez; Matthias Loebe; Scott A Scheinin; Brian A Bruckner
Journal:  Transplant Direct       Date:  2018-10-25

Review 6.  Infectious Complications Following Solid Organ Transplantation.

Authors:  Alexis Guenette; Shahid Husain
Journal:  Crit Care Clin       Date:  2019-01       Impact factor: 3.598

7.  The Impact of Antifungal Prophylaxis in Lung Transplant Recipients.

Authors:  Kelly M Pennington; Hayley J Dykhoff; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah; Steve G Peters; Jason N Barreto; Raymund R Razonable; Cassie C Kennedy
Journal:  Ann Am Thorac Soc       Date:  2021-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.